Lack of specificity for the analysis of raltegravir using online sample clean-up liquid chromatography-electrospray tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 877, Issue 29, 2009, Pages 3734-3738

  Jourdil, Jean François ^a   Bartoli, Mireille ^a   Stanke Labesque, Françoise ^a,b,c  

^a HÔPITAL MICHALLON   (France)

^b University Grenoble Alpes   (France)

^c UNIV GRENOBLE ALPES   (France)

Author keywords

In source transformation; Mass spectrometry; Raltegravir; Raltegravir glucuronide

Indexed keywords

DRUG PRODUCTS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PATIENT MONITORING; PATIENT TREATMENT; VIRUSES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; GLUCURONIDES; HUMAN IMMUNODEFICIENCY VIRUS-1; LIQUID CHROMATOGRAPHY ELECTROSPRAY; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (LC MS/MS); MULTIPLE REACTION MONITORING; RALTEGRAVIR; SOURCE TRANSFORMATION;

DISEASES;

ANTIRETROVIRUS AGENT; CARBON 13; RALTEGRAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; DRUG DETERMINATION; DRUG GLUCURONIDATION; DRUG MONITORING; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; ISOTOPE LABELING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; ONLINE ANALYSIS; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 72049118147     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.08.031     Document Type: Article

References (11)

1. Vogeser M., Zachoval R., Spohrer U., and Jacob K. Ther. Drug Monit. 23 (2001) 722
2. Cocohoba J., and Dong B.J. Clin. Ther. 30 (2008) 1747
3. Kassahun K., McIntosh I., Cui D., Hreniuk D., Merschman S., Lasseter K., Azrolan N., Iwamoto M., Wagner J.A., and Wenning L.A. Drug Metab. Dispos. 35 (2007) 1657
4. Iwamoto M., Wenning L.A., Nguyen B.Y., Teppler H., Moreau A.R., Rhodes R.R., Hanley W.D., Jin B., Harvey C.M., Breidinger S.A., Azrolan N., Farmer Jr. H.F., Isaacs R.D., Chodakewitz J.A., Stone J.A., and Wagner J.A. Clin. Infect. Dis. (2009)
5. Merschman S.A., Vallano P.T., Wenning L.A., Matuszewski B.K., and Woolf E.J. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 857 (2007) 15
6. Long M.C., Bennetto-Hood C., and Acosta E.P. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 867 (2008) 165
7. Ter Heine R., Hillebrand M.J., Rosing H., van Gorp E.C., Mulder J.W., Beijnen J.H., and Huitema A.D. J. Pharm. Biomed. Anal. 49 (2009) 451
8. Fayet A., Beguin A., Zanolari B., Cruchon S., Guignard N., Telenti A., Cavassini M., Gunthard H.F., Buclin T., Biollaz J., Rochat B., and Decosterd L.A. J. Chromatogr. B Analyt. Technol. Biomed. Life. Sci. 877 (2009) 1057
9. Koal T., Burhenne H., Romling R., Svoboda M., Resch K., and Kaever V. Rapid Commun. Mass Spectrom. 19 (2005) 2995
10. U.S. Department of Health and Human Services Food and Drug Administration, Guidance for Industry Bioanalytical Method Validation, http://www.fda.gov/CDER/GUIDANCE/4252fnl.htm, 2001, April 23, 2008.
11. Heinisch S., and Rocca J.L. J. Chromatogr. A 1216 (2009) 642